Breaking Finance News

A report released today by Cantor Fitzgerald about Vernalis PLC (LON:VER) bumps down the target price to 101.00GBX

In a report released on Thursday October 13, 2016 Cantor Fitzgerald reduced the stock price target of Vernalis PLC (LON:VER) from 118.00GBX to 101.00GBX indicating a possible upside of 1.56%.

Previously on Thursday September 29, 2016, Stifel reported on Vernalis PLC (LON:VER) held steady the target price at 99.00GBX. At the time, this indicated a possible upside of 1.44%.

Yesterday Vernalis PLC (LON:VER) traded -1.88% lower at 39.50GBX. The company’s 50-day moving average is 42.26GBX and its 200-day moving average is 44.77GBX. With the last close down -12.32% relative to the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. Trade Volume was down over the average, with 88,040 shares of VER changing hands under the typical 188,306

Recent Performance Chart

Vernalis PLC (LON:VER)

Vernalis PLC has with a one year low of 31.00GBX and a one year high of 75.00GBX and has a total market value of 0 GBX.

A total of 5 equity analysts have released a research note on VER. Two equity analysts rating the company a strong buy, two equity analysts rating the company a buy, one equity analyst rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of 83.60GBX.

Brief Synopsis About Vernalis PLC (LON:VER)

Vernalis plc is a commercial-stage pharmaceutical holding company. The Company is engaged in the research, development and commercialization of pharmaceutical products for a range of medical disorders. The Company has two marketed products: Tuzistra XR in the United States prescription cough cold market, and frovatriptan, an acute treatment for migraine. The Company also has four prescription cough cold products under development, and a pipeline of research and new chemical entity (NCE) development programs. Its commercial pipeline candidates include CCP-05, CCP-06, CCP-07 and CCP-08. The Company operates in the United Kingdom, Rest of Europe, North America and Rest of the World. The Company is also engaged in fragment- and structure-based drug discovery. It has two development products in the central nervous system (CNS) therapeutic area: the fatty acid amide hydrolase (FAAH) inhibitor V158866 for pain, and V81444, an adenosine A2A receptor antagonist as a treatment for CNS diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.